These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37719058)

  • 1. BRCA1 and BRCA2 mutations and their clinical relevance in selected women diagnosed with triple-negative breast cancer in Kenya: a descriptive cross-sectional study.
    Rioki JN; Muchiri L; Mweu M; Nyagol J; Songok E; Mwangi J; Oyaro M; Ong'ang'o LB; Rogena E
    Pan Afr Med J; 2023; 45():102. PubMed ID: 37719058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
    Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
    Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer.
    Wang X; Liu H; Maimaitiaili A; Zhao G; Li S; Lv Z; Wu D; Shi A; Guan X; Jia H; Li M; Song D; Kang L; Han B; Fu T; Yang M; Zhu Z; Du Y; Song Y; Hong J; Fan Z
    Mol Genet Genomic Med; 2019 Jun; 7(6):e677. PubMed ID: 30968603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.
    Melki R; Melloul M; Aissaoui S; El Harroudi T; Boukhatem N
    BMC Cancer; 2023 Apr; 23(1):339. PubMed ID: 37055759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
    Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
    JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
    Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
    BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
    Ryu JM; Choi HJ; Kim I; Nam SJ; Kim SW; Yu J; Lee SK; Choi DH; Park YH; Kim JW; Seo JS; Park JH; Lee JE; Kim SW;
    Breast Cancer Res Treat; 2019 Jan; 173(2):385-395. PubMed ID: 30350268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of next-generation sequencing in detection of BRCA1/2 and homologous recombination repair pathway multi-genes germline mutation and correlation analysis].
    Chen YL; Zhuo ZL; Liu C; Xie F; Yang ZY; Liu PF; Wang S; Zhao XT
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Mar; 56(3):302-311. PubMed ID: 35381651
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.
    Muendlein A; Rohde BH; Gasser K; Haid A; Rauch S; Kinz E; Drexel H; Hofmann W; Schindler V; Kapoor R; Decker T; Lang AH
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2005-12. PubMed ID: 25971625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
    Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
    Duan RR; Sun LX; Zhao HW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292
    [No Abstract]   [Full Text] [Related]  

  • 13. Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors.
    Hata C; Nakaoka H; Xiang Y; Wang D; Yang A; Liu D; Liu F; Zou Q; Wei L; Zheng K; Inoue I; You H
    J Hum Genet; 2020 Jul; 65(7):577-587. PubMed ID: 32029870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
    Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
    BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family.
    Liao Y; Tu C; Song X; Cai L
    J Assist Reprod Genet; 2020 Jun; 37(6):1489-1495. PubMed ID: 32356124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer.
    Villarreal-Garza C; Weitzel JN; Llacuachaqui M; Sifuentes E; Magallanes-Hoyos MC; Gallardo L; Alvarez-Gómez RM; Herzog J; Castillo D; Royer R; Akbari M; Lara-Medina F; Herrera LA; Mohar A; Narod SA
    Breast Cancer Res Treat; 2015 Apr; 150(2):389-94. PubMed ID: 25716084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic alterations in sporadic triple negative breast cancer.
    Pop LA; Cojocneanu-Petric RM; Pileczki V; Morar-Bolba G; Irimie A; Lazar V; Lombardo C; Paradiso A; Berindan-Neagoe I
    Breast; 2018 Apr; 38():30-38. PubMed ID: 29202330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
    Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
    BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
    Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M
    Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
    Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
    BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.